R Pharm competitive analysis

Explore patent oppositions filed by R Pharm against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIASep 28, 2023
Antitumor T Cell Response EnhancerCHUGAI SEIYAKU KABUSHIKI KAISHAJul 25, 2023
Early Intervention Methods To Prevent Or Ameliorate ToxicitySEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RESEARCH INSTITUTESep 20, 2022
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIAOct 6, 2021
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIANov 25, 2020
Method For Producing Disintegrating Particulate Composition Comprising Acid-Type Carboxymethylcellulose, Disintegrating Particulate Composition Comprising Acid-Type Carboxymethylcellulose, And Orally Disintegrating Tablet Including Disintegrating Particulate Composition Comprising Acid-Type CarboxymethylcelluloseDAICELApr 16, 2020
Indazole Compounds As Irak4 InhibitorsAURIGENE DISCOVERYDec 11, 2019
Identification Of Patients In Need Of Pd-L1 Inhibitor CotherapyF HOFFMANN LA ROCHEAug 7, 2019
Ion Exchange Membrane ChromatographyF HOFFMANN LA ROCHEJun 12, 2019
Method To Improve Virus Removal In Protein PurificationF HOFFMANN LA ROCHEOct 10, 2018

Explore R Pharm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Aug 17, 2016Method For The Treatment Of Glomerulonephritis1

Latest PTAB cases involving R Pharm

Discover the latest PTAB cases involving R Pharm, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing R Pharm with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
CELATOR PHARMACEUTICALS - 8 - -
GENERICS UK319 - - -
SANDOZ1472619 -
TEVA PHARMACEUTICAL INDUSTRIES LTD2727 - -